Totilac Dosing in ESRD Patients with Hemorrhagic Stroke
I cannot provide dosing recommendations for "Totilac" (hypertonic lactate solution) in ESRD patients with hemorrhagic stroke because the evidence provided does not contain any FDA-approved drug labeling or clinical guidelines for this specific medication in this population.
Critical Evidence Gap
The FDA drug labels provided 1 are for ketorolac tromethamine (Toradol), not Totilac (hypertonic lactate solution). These are completely different medications with different mechanisms of action, indications, and safety profiles.
What the Evidence Actually Shows
Hypertonic Lactate in Brain Injury (Not Hemorrhagic Stroke)
- Hypertonic lactate has been studied for intracranial hypertension in traumatic brain injury, not hemorrhagic stroke 2, 3.
- One study used half-molar sodium lactate (0.5 mL/kg/h continuous infusion for 48 hours) to prevent elevated intracranial pressure in severe traumatic brain injury patients 3.
- Another study used 7.5% hypertonic lactate at equi-osmolar (2400 mOsmol/L) and isovolumic (1.5 mL/kg) bolus doses for intracranial hypertension in acute brain injury 2.
Hemorrhagic Stroke Guidelines Do Not Mention Hypertonic Lactate
- The 2022 American Heart Association/American Stroke Association guidelines for spontaneous intracerebral hemorrhage recommend hypertonic saline or mannitol for cerebral edema management, with hypertonic saline being more effective than mannitol in equiosmolar doses 4.
- No guideline evidence supports the use of hypertonic lactate specifically for hemorrhagic stroke 5, 6, 4.
ESRD Considerations
- Stroke patients have an elevated risk of developing ESKD (adjusted hazard ratio 1.79), and this risk is present in both hemorrhagic and ischemic stroke 7.
- The ischemic stroke guidelines note that IV alteplase is recommended in ESRD patients on hemodialysis with normal aPTT, but this relates to thrombolytic therapy, not osmotic agents 6.
Clinical Recommendation
For ESRD patients with hemorrhagic stroke requiring hyperosmolar therapy for cerebral edema, use hypertonic saline rather than experimental agents. The 2022 AHA/ASA guidelines support hypertonic saline as more effective than mannitol for treating elevated intracranial pressure 4. Hypertonic saline can be administered as bolus doses (typically 23.4% or 3% concentrations) with appropriate monitoring of serum sodium and chloride 8.
Totilac (hypertonic lactate) does not have established dosing, safety data, or regulatory approval for use in hemorrhagic stroke patients, particularly those with ESRD. Any use would be off-label and experimental, requiring institutional review board approval and informed consent.